DELIX THERAPEUTICS
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale.
DELIX THERAPEUTICS
Industry:
Biotechnology Health Care Life Science
Founded:
2019-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.delixtherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
118 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Content Delivery Network Microsoft Exchange Online Amazon Office 365 Mail
Similar Organizations
Aracari Biosciences
Aracari is a Drug discovery company.
Lunac Therapeutics
Lunac Therapeutics is a UK-based drug discovery company.
Current Advisors List
Board_member
Current Employees Featured
Brigitte Robertson Chief Medical Officer @ Delix Therapeutics
Chief Medical Officer
2021-08-01
Retsina Meyer Head of Strategic Projects and Alliances @ Delix Therapeutics
Head of Strategic Projects and Alliances
2021-03-01
Mark Rus Chief Executive Officer @ Delix Therapeutics
Chief Executive Officer
2021-03-01
David E. Olson CO-founder, president @ Delix Therapeutics
CO-founder, president
2021-07-01
Nick Haft Co-Founder @ Delix Therapeutics
Co-Founder
2019-07-01
Founder
Investors List
Comerica - Technology & Life Sciences
Comerica - Technology & Life Sciences investment in Debt Financing - Delix Therapeutics
WPSS Investments
WPSS Investments investment in Series A - Delix Therapeutics
Bail Capital
Bail Capital investment in Series A - Delix Therapeutics
Vertical Venture Partners
Vertical Venture Partners investment in Series A - Delix Therapeutics
Negev Capital
Negev Capital investment in Series A - Delix Therapeutics
Casa Verde Capital
Casa Verde Capital investment in Series A - Delix Therapeutics
OMX Ventures
OMX Ventures investment in Series A - Delix Therapeutics
RA Capital Management
RA Capital Management investment in Series A - Delix Therapeutics
Apeiron Holdings Limited
Apeiron Holdings Limited investment in Series A - Delix Therapeutics
Ocama Partners
Ocama Partners investment in Series A - Delix Therapeutics
Key Employee Changes
Date | New article |
---|---|
2021-08-02 | Delix Therapeutics Continues Rapid Growth with Appointment of Chief Medical Officer |
Official Site Inspections
http://www.delixtherapeutics.com Semrush global rank: 3.92 M Semrush visits lastest month: 3.22 K
- Host name: ec2-54-237-159-171.compute-1.amazonaws.com
- IP address: 54.237.159.171
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
Delixtherapeutics.com lookup results from whois.srsplus.com server:
- Domain created: 19th-Feb-2019
- Domain updated: 6th-Jun-2023
- Domain expires: 19th-Feb-2025 0 Years, 38 Days left
- Website age: 5 Years, 327 Days
- Registrar Domain ID: 2362071409_DOMAIN_COM-VRSN
- Registrar Url: http://www.srsplus.com
- Registrar WHOIS Server: whois.srsplus.com
- Registrar Abuse Contact Email: domain.operations@web.com
- Registrar Abuse Contact Phone: +1.8777228662
- Name server:
- NS11.CONSTELLIX.COM
- NS21.CONSTELLIX.COM
- NS31.CONSTELLIX.COM
- NS41.CONSTELLIX.NET
- NS51.CONSTELLIX.NET
- NS61.CONSTELLIX.NET
More informations about "Delix Therapeutics"
Delix Therapeutics - Wikipedia
In 2021, Delix was named one of the Fierce 15 of Biotech. In 2022, Nature named Delix Spinout of the Year and Delix was awarded the Healthcare Businesswomen's Association (HBA) ACE award. In 2023, Delix was a finalist for the Prix Galien award for Best Startup and the BWB award for Biotech Innovation of the Year and won the Biotech Breakthrough Award for Neuroscience Therapeutics Company of the Year. See details»
Delix Therapeutics - Crunchbase Company Profile
Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.See details»
Delix Company Profile 2024: Valuation, Funding & Investors
Information on valuation, funding, cap tables, investors, and executives for Delix. Use the …See details»
Our Team Pushing the Boundaries of Neuroscience - Delix …
Meet the team of Delix innovators pushing the frontiers of neuroscience and developing novel …See details»
Delix Therapeutics - LinkedIn
Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class ...See details»
For Investors - Delix Therapeutics
Join world class investors partnered with Delix to support pursuing advanced neurological treatments leveraging rapid, sustained & scalable neuroplastogensSee details»
UC Davis-Enabled Startup Delix Therapeutics Secures …
By Neelanjana Gautam October 8, 2021 UC Davis-enabled neuroscience startup Delix Therapeutics recently closed a $70 million Series A funding round. Co-founded by David E. Olson, associate professor in the Department of …See details»
Delix Therapeutics Awarded National Institutes of Health Grant to ...
BEDFORD, Mass., December 13, 2023--Delix Therapeutics Awarded National Institutes of …See details»
Delix
Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics.See details»
Delix raises $70 million to synthesize psychedelic-inspired drugs
Sep 27, 2021 In 2019, Olson cofounded Delix to recruit a team of chemists up to the task. …See details»
Delix Therapeutics Expands Executive Leadership Team - PR …
BOSTON, July 6, 2021 /PRNewswire/ -- Preclinical neuroscience company Delix Therapeutics …See details»
Pioneering Next-Gen Neuroplasticity Therapies - Delix Therapeutics
At Delix, our singular focus is pushing the boundaries of neuroscience to treat conditions of the …See details»
Delix Announces DLX-001 Demonstrates Evidence of CNS …
BEDFORD, Mass., May 13, 2024--Delix Therapeutics, a clinical-stage neuroscience company …See details»
Nature Biotechnology Selects Delix Therapeutics as a Leading …
Fast growing neuroscience company featured by Nature as a top academic spinout, …See details»
Delix Therapeutics Closes $70 Million Series A Financing to …
BOSTON, Sept. 27, 2021 /PRNewswire/ -- Preclinical neuroscience company Delix …See details»
Delix Announces DLX-001 Demonstrates Evidence of CNS …
May 13, 2024 Investor Relations: Retsina Meyer, PhD Delix Therapeutics …See details»
Delix Therapeutics Co-Founder Publishes Groundbreaking Study ...
BOSTON, April 28, 2021 /PRNewswire/ -- Delix Therapeutics, a preclinical biotech company …See details»
Delix in the News - Delix Therapeutics
Find the latest news articles, media, and press releases about Delix Therapeutics’ scientific, …See details»
Delix Pipeline of Psychoplastogens and Neuroplastogens - Delix …
Our diversified pipeline lauds more than 1500 compounds based on more than 10 unique …See details»